CHRONIC KIDNEY DISEASE

Slides:



Advertisements
Similar presentations
Multicenter database of clinical course of CKD patients Internal Medicine Jang Hye Ryoun.
Advertisements

William Vega-Ocasio MD. Internal Medicine - Nephrology
End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.
Recent Advances in Management of CRF Yousef Boobess, M.D. Head, Nephrology Division Tawam Hospital.
Renal Replacement Therapy: What the PCP Needs to Know.
CKD In Primary Care Dr Mohammed Javid.
18 week commissioning pathways for kidney disease and renal transplantation Specialty Clinical Leads Lawrence Goldberg: CKD and ESRF pathways John Scoble:
Lesley Stevens MD Tufts-New England Medical Center
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Approach to Advanced Kidney Disease Management in the Elderly Source: Schell JO, Germain MJ, Finkelstein FO, et al. An integrative approach to advanced.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
RENAL DISEASE IN DIABETES
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
UKRR Dataset v4.1 How does it fit with the UKRDC ACTIONS IN YOUR RENAL UNIT TO IMPLEMENT THE NEW DATASET UK RENAL REGISTRY 2015 INFORMATICS MEETING: DATA.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Diabetes And Hemodialysis 1 Dr.Ruba Nashawati. 2.
Kidney disease burden and available Renal transplantation and Dialysis services in India Dr. Sham Sunder.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Section 1: CKD Epidemiology
- Higher SBP visit-to-visit variability (SBV) has been associated
Nephrology Journal Club The SPRINT Trial Parker Gregg
The LIVES Sub-analysis
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Darshika Chhabra, MD, MPH
The role of unknown risk factors in coronary heart disease
Hypertension guidelines What’s all the controversy about 2015
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Assessment and Diagnosis of Renal Dysfunction in the ICU
Evidence-based Medicine
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
Lead for the quantitative evaluation
Mortality rates in incident ESRD patients figure 9
2017 Annual Data Report Healthy People 2020.
What’s New in the 2013 ESC/ESH Hypertension Guideline
The Anglo Scandinavian Cardiac Outcomes Trial
Presentation for Community Leadership
Current and future management of diabetic renal failure
Empagliflozin (Jardiance®)
Acute and Chronic Renal Failure
RAAS Blockade: Focus on ACEI
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
The percentage of subjects with de novo development of renal function impairment (GFR
Diuretics, Kidney Diseases Urine R&M
2018 Annual Data Report Volume 3: Healthy People 2020
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Section 5: Configuration of healthcare to manage CKD
Tips for Written assignment HSNS265
Meeting the challenges of the new K/DOQI guidelines
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Presentation for Health Care Staff & Health Stakeholders
World Kidney Day 2016: Kidney Disease & Children
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
Volume 62, Issue 4, Pages (October 2002)
Hypertension Implementing NICE guidance 2 nd Edition March 2013 NICE clinical guideline 127.
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
END STAGE RENAL DISEASE The BVI Experience
Presentation transcript:

CHRONIC KIDNEY DISEASE

Immune system in CKD and infection in GN pts In CKD and HD patients dysfunction of immune system alterations belonge to involving innate and adaptive immunity in T and B lymphocytes (Reduced T regulatory cells and memory cells and increased innate cells). In GN patients on IS th is important to put correct diagnosis and treatment of infection, as well as weighing the risk of infection with the risk of untreated glomerular disease

ANCA vasculitis, SLE and MGRS New drugs in treatment ANCA vasculitis and SLE are not well established. In patients with MGRS the role of nephrologist is to perform kidney Bx in order to assess the MGRS type and evaluate the severity of renal disease

Alport and Fabry 27% of heterozygous women with XLAS (COL4A5 mutation) develop ESRD. For the DG of Fabry disease you must think that it could be

Oncology patients and elderly outpatients It is important to estimate of renal function in oncology patients (GFR formulas adjusted for body surface area) In elderly outpatient drug-related clinically relevant blood pressure overtreatment, resulting in hypotension.

Contrast induce AKI Although there is evidence that CI-AKI is associated with worse outcomes, there is no evidence of a causal relationship or that reducing CI-AKI improves overall outcome. To date there has been no conclusive benefit demonstrated from interventions except for low osmolar or iso-osmolar contrast and IV hydration.

How to retarding the transition from CKD to ESRD Detection of CKD at risk groups and referral to nephrology in CKD 3B stage Good partnership and education of the primary care physicians and other specialties Dialysis access should be placed sufficiently early to preclude the need for central venous catheters Patients education (low-protein diets; ketoanalogs; correct metabolic acidosis; oral antioxidants)

HEMODIALYSIS

Vascular access In elderly patients is more difficult to construct permanent vascular access and is appropriate starting with a tunnel rather than a temporary catheter. Between diabetics and non-diabeticsIn there is no significant difference in color Doppler findings but successful creation of VA in diabetics is less common

Vascular calcification Think about association between vascular calcification and anticoagulation therapy (old and new) in CKD and HD patients. Potential role of indoxyl sulphate as an uremic toxin in delopment od LVH in ESRD.

CV disease In ESRD patients clinical, diagnostic and therapeutic approach of different CV manifestation differ from that in non-dialysis population and outcome is less favourable

Oxidative stress in HD patients HD patients mortality is associated with higher inflammation and OS. Biomarkers of inflammation (hsCRP), oxidative stress (PAB) and hsTnI are good predictors of all-cause and CVD mortality. The combination of 2 biomarkers of different pathophisiological pathways proved to be better tool for the assessment of all-cause and CVD mortality than single biomarker

Fraility Nephrologists should actively attempt to identify the frail patients with CKD because they are more likely to require hospitalization and more likely to die than their non-frail counterparts.

Kidney transplantation

14th BANTAO congress confirmed Great difference between Balkan countries in number and development of kidney Tx

The development of transplantation program in countries with small number of kidney Tx improved many medical fields and provided continuous education of medical staff

Donor program Severe organ shortage crisis represents a universal challange which should be faced under the scope of a planned and integrated approach primarily focused on solutions to increase deceased organ donation. Organisation model, legislation and public opinion are necessary frame, but proactive hospital approach to organ donation is mandatory to expand the national pool of solid organs for transplantation.

Hypertension after kidney Tx Elevated BP levels post-transplant identify patients at high risk of AR independently of graft function. CCB is useful in antagonizing the vc effects of CNI. The RAS inhibitors seem a good option, especially in patients with proteinuria, but their effects on long-term graft and patient survival are controversial. β -Blockers could be beneficial in pts with coronary heart disease Thiazide diuretics could be the reasonable option for patients with glomerular filtration rate ≥30 mL/min/1.73 m2

HCV and Tx Patients with HCV infection should be transplanted but the timing of treatment (before or after TX) should be individualized Direct acting antiviral therapy have revolutionarized the field

IgA and kidney Tx Recurrence of IgA nephropathy is common after kidney Tx, especially in young patients, and may be more prevalent in those who receive their transplant from living related donors. IS therapy specifically directed toward treatment of recurrent IgA may be used in selected patients. The majority of studies demonstrate that overall graft survival in those with IgAN is no worse than those with other causes of ESRD.